{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:07:32Z","timestamp":1793142452185,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,30]],"date-time":"2014-07-30T00:00:00Z","timestamp":1406678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100005451","name":"Library of Congress","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000092","name":"U.S. National Library of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institute for Biological Products Control"},{"name":"National Institutes for Food and Drug Control"},{"name":"Center for Biologics Research and Evaluation"},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.biologicals.2014.07.003","type":"journal-article","created":{"date-parts":[[2014,8,16]],"date-time":"2014-08-16T04:15:21Z","timestamp":1408162521000},"page":"223-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Adventitious agents in viral vaccines: Lessons learned from 4 case studies"],"prefix":"10.1016","volume":"42","author":[{"given":"John","family":"Petricciani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sheets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elwyn","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2014.07.003_bib1","unstructured":"Regulatory risk evaluation on finding an adventitious agent in a marketed vaccine: scientific principles to consider. http:\/\/www.who.int\/biologicals."},{"key":"10.1016\/j.biologicals.2014.07.003_bib2","series-title":"Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Replacement of TRS 878","year":"2013"},{"issue":"2","key":"10.1016\/j.biologicals.2014.07.003_bib3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0042-6822(57)90100-9","article-title":"The induction of neoplasms with a substance released from mouse tumors by tissue culture","volume":"3","author":"Stewart","year":"1957","journal-title":"Virology"},{"key":"10.1016\/j.biologicals.2014.07.003_bib4","first-page":"747","article-title":"Neoplasms in hamster induced by mouse tumor agent passed in tissue culture","volume":"20","author":"Eddy","year":"1958","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.biologicals.2014.07.003_bib5","series-title":"United States Senate. 93rd Congress","first-page":"549","article-title":"Hearings before the subcommittee on executive reorganization and government research of the committee on government operations","year":"1972"},{"key":"10.1016\/j.biologicals.2014.07.003_bib6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3181\/00379727-105-26128","article-title":"The vacuolating virus, S.V. 40","volume":"105","author":"Sweet","year":"1960","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.biologicals.2014.07.003_bib7","first-page":"183","article-title":"Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines","volume":"94","author":"Hilleman","year":"1998","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.biologicals.2014.07.003_bib8","series-title":"Networks of innovation: vaccine development at merck","first-page":"79","author":"Galambos","year":"1895"},{"issue":"7177","key":"10.1016\/j.biologicals.2014.07.003_bib9","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(61)92273-5","article-title":"Poliomyelitis vaccines","volume":"277","author":"Goffe","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.biologicals.2014.07.003_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3181\/00379727-108-26843","article-title":"Clinical and serological responses in volunteers given vacuolating virus (OSV40) by respiratory route","volume":"108","author":"Morris","year":"1961","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.biologicals.2014.07.003_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3181\/00379727-108-26892","article-title":"Inactivanon of vacuolating virus (SV40) by formaldehyde","volume":"108","author":"Gerber","year":"1961","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.biologicals.2014.07.003_bib12","series-title":"Requirements for poliomyelitis vaccine (oral): report of a study group","author":"Requirements for Biological Substances 7","year":"1962"},{"key":"10.1016\/j.biologicals.2014.07.003_bib13","series-title":"Report of the technical committee on poliomyelitis vaccine: presence of vacuolating agent in poliomyelitis vaccine","year":"1961"},{"key":"10.1016\/j.biologicals.2014.07.003_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3181\/00379727-107-26576","article-title":"Tumors induced in hamsters by injection of rhesus monkey kidney cell extracts","volume":"107","author":"Eddy","year":"1961","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.biologicals.2014.07.003_bib15","series-title":"Report of the technical committee on poliomyelitis vaccine: presence of vacuolating agent in poliomyelitis vaccine","year":"1961"},{"key":"10.1016\/j.biologicals.2014.07.003_bib16","series-title":"Developments with respect to the manufacture of live poliovirus vaccine and results of utilization of killed virus polio vaccine","author":"Hearings before a Subcommittee of the Committee on Interstate and Foreign Commerce of the House of Representatives","year":"1961"},{"key":"10.1016\/j.biologicals.2014.07.003_bib17","series-title":"Conference on production and testing and requirements for live poliovirus vaccine","author":"Department of Health, Education, and Welfare","year":"1960"},{"key":"10.1016\/j.biologicals.2014.07.003_bib18","series-title":"Part 73 biological products, safety standards: poliomyelitis vaccine, adenovirus vaccine","first-page":"2109","author":"Code of Federal Regulations","year":"1963"},{"issue":"1","key":"10.1016\/j.biologicals.2014.07.003_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/biol.1999.0233","article-title":"Live oral poliovirus vaccines do not contain detectable simian virus 40 (SV40) DNA","volume":"28","author":"Sierra-Honigmann","year":"2000","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2014.07.003_bib20","series-title":"Second International Conference on Live Poliovirus Vaccines","first-page":"79","article-title":"Detection of a 'Non-Detectable' simian virus (vacuolating agent) present in rhesus and cynomolgus monkey kidney cell culture material: a preliminary report","author":"Sweet","year":"1960"},{"issue":"12","key":"10.1016\/j.biologicals.2014.07.003_bib21","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.1961.73040510005008","article-title":"Live poliovirus vaccines \u2013 present status and problems for the future","volume":"178","author":"Koprowski","year":"1961","journal-title":"J\u00a0Am Med Assoc"},{"issue":"2","key":"10.1016\/j.biologicals.2014.07.003_bib22","first-page":"185","article-title":"Simian virus 40, polio vaccines, and human caner: research progress\u00a0versus media and public interest","volume":"78","author":"Butel","year":"2000","journal-title":"Bull World Health Organ"},{"issue":"2","key":"10.1016\/j.biologicals.2014.07.003_bib23","first-page":"91","article-title":"Isolation of bacteriophages from commercial sera","volume":"8","author":"Merril","year":"1972","journal-title":"In\u00a0Vitro"},{"key":"10.1016\/j.biologicals.2014.07.003_bib24","first-page":"31","article-title":"Bacterial virus contamination of fetal bovine sera","volume":"9","author":"Chu","year":"1973","journal-title":"In\u00a0Vitro"},{"issue":"3","key":"10.1016\/j.biologicals.2014.07.003_bib25","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3181\/00379727-144-37683","article-title":"Bacteriophages in live virus vaccines","volume":"144","author":"Petricciani","year":"1973","journal-title":"Proc Soc Exp Biol Med"},{"issue":"3","key":"10.1016\/j.biologicals.2014.07.003_bib26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3181\/00379727-158-40209","article-title":"Characteristics of bacteriophage NV-1 isolated from live virus vaccines","volume":"158","author":"Haselkorn","year":"1978","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.biologicals.2014.07.003_bib27","unstructured":"Ad hoc advisory committee: Thomas F. Anderson (Institute for Cancer Research), Edward L. Buescher (Walter Reed Army Institute of Research), Seymour Cohen (University of Colorado), Harry Eagle (Albert Einstein College of Medicine), Robert Haselkorn (University of Chicago), Samuel L. Katz (Duke University School of Medicine), Saul Krugman (New York University), Edwin H. Lennette (California State Department of Health), Albert Sabin (Fogarty International Center), John Seal (National Institute of Allergy and Infectious Diseases), and David J. Sencer (Center for Disease Control)."},{"key":"10.1016\/j.biologicals.2014.07.003_bib28","first-page":"11080","volume":"vol. 38","author":"Federal Register","year":"1973"},{"key":"10.1016\/j.biologicals.2014.07.003_bib29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0035-9203(44)90037-4","article-title":"Bacteriophage treatment in bacillary dysentery","volume":"37","author":"Boyd","year":"1944","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.biologicals.2014.07.003_bib30","first-page":"357","article-title":"An experimental study on the usefulness of bacteriophage in the prophylaxis and treatment of cholera","volume":"28","author":"Dutta","year":"1963","journal-title":"Bull World Health Organ"},{"issue":"12","key":"10.1016\/j.biologicals.2014.07.003_bib31","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1172\/JCI106756","article-title":"Immunologic responses to bacteriophage NX-174 in immunodeficiency diseases","volume":"50","author":"Ochs","year":"1971","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.biologicals.2014.07.003_bib32","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3181\/00379727-158-40208","article-title":"Bacteriophages, vaccines, and people: an assessment of risk","volume":"158","author":"Petricciani","year":"1978","journal-title":"Proc Soc Exp Biol Med"},{"issue":"4302","key":"10.1016\/j.biologicals.2014.07.003_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1126\/science.406673","article-title":"Bacteriophages in live virus vaccines: lack of evidence for effects on the genome of rhesus monkeys","volume":"197","author":"Milstien","year":"1977","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biologicals.2014.07.003_bib34","first-page":"543","article-title":"The cytogenetic, proliferative and viability effects of four bacteriophages on human lymphocytes","volume":"14","author":"Wenger","year":"1978","journal-title":"In\u00a0Vitro"},{"key":"10.1016\/j.biologicals.2014.07.003_bib35","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1073\/pnas.91.4.1544","article-title":"Ultrasenstivie retrovirus detection by a reverse-transcriptase assay based on product enhancement","volume":"91","author":"Pyra","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biologicals.2014.07.003_bib36","series-title":"Reverse transcriptase activity in chicken-cell derived vaccines","first-page":"209","year":"1998"},{"key":"10.1016\/j.biologicals.2014.07.003_bib37","volume":"vol. 897","author":"WHO","year":"1998"},{"issue":"2","key":"10.1016\/j.biologicals.2014.07.003_bib38","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/JCM.39.2.675-684.2001","article-title":"No evidence of infectious retroviruses in measles virus vaccines produced in chicken embryo cell cultures","volume":"39","author":"Shahbuddin","year":"2001","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.biologicals.2014.07.003_bib39","first-page":"105","article-title":"Expert committee on biological standardization: highlights of the 45th meeting, October 1995","volume":"vol. 71","author":"WHO","year":"1996"},{"key":"10.1016\/j.biologicals.2014.07.003_bib40","volume":"vol. 872","author":"WHO","year":"1995"},{"issue":"1","key":"10.1016\/j.biologicals.2014.07.003_bib41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3201\/eid0701.010111","article-title":"Lack of evidence of endogenous avian leukosis virus and endogenous avian retrovirus transmission to measles, mumps, and rubella vaccine recipients","volume":"7","author":"Hussain","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.biologicals.2014.07.003_bib42","series-title":"Unexpected protein found in measles-mumps vaccine \u2013 entity said to be from chickens, harmless to humans","year":"1995"},{"key":"10.1016\/j.biologicals.2014.07.003_bib43","first-page":"140","volume":"vol. 12","author":"Reverse transcriptase activity in vaccines","year":"1998"},{"key":"10.1016\/j.biologicals.2014.07.003_bib44","doi-asserted-by":"crossref","unstructured":"Victoria JG, Wang C, Jones MS, Jaing C, McLoughlin K, Gardner S, et\u00a0al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus, J Virol, doi:10.1128\/JVI.02690-09.","DOI":"10.1128\/JVI.02690-09"},{"issue":"29\u201330","key":"10.1016\/j.biologicals.2014.07.003_bib45","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1016\/j.vaccine.2011.04.087","article-title":"Molecular and infectivity studies of porcine circovirus in vaccines","volume":"29","author":"McClenahan","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2014.07.003_bib46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.vaccine.2010.11.028","article-title":"Analysis of porcine circovirus type 1 detected in rotarix vaccine","volume":"29","author":"Baylis","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.biologicals.2014.07.003_bib47","unstructured":"http:\/\/www.who.int\/vaccine_safety\/topics\/rotavirus\/rotarix_statement_march_2010\/en\/index.html."},{"key":"10.1016\/j.biologicals.2014.07.003_bib48","unstructured":"http:\/\/www.who.int\/immunization\/Interim_report_Flu_Rotarix_16_Apr_draft_v1.pdf."},{"key":"10.1016\/j.biologicals.2014.07.003_bib49","unstructured":"http:\/\/www.who.int\/immunization\/newsroom\/news_rotavirus_vaccine_use\/en\/index.html."},{"key":"10.1016\/j.biologicals.2014.07.003_bib50","unstructured":"http:\/\/www.who.int\/wer\/2010\/wer8522.pdf."},{"key":"10.1016\/j.biologicals.2014.07.003_bib51","unstructured":"http:\/\/www.who.int\/immunization_standards\/vaccine_quality\/PCV1_questions_answers_21apr10.pdf."},{"key":"10.1016\/j.biologicals.2014.07.003_bib52","unstructured":"http:\/\/www.who.int\/vaccine_safety\/committee\/reports\/Jun_2010\/en\/."},{"issue":"3","key":"10.1016\/j.biologicals.2014.07.003_bib53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1399-3089.2004.00134.x","article-title":"Infection studies on human cell lines with porcine circovirus type 1 and porcine circovirus type 2","volume":"11","author":"Hattermann","year":"2004","journal-title":"Xenotransplantation"},{"issue":"6","key":"10.1016\/j.biologicals.2014.07.003_bib54","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.biologicals.2013.09.005","article-title":"The serological evidence in humans supports a negligible risk of zoonotic infection from porcine circovirus type 2","volume":"41","author":"Burbelo","year":"2013","journal-title":"Biologicals"},{"key":"10.1016\/j.biologicals.2014.07.003_bib55","unstructured":"http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2010\/07\/news_detail_001059.jsp&mid=WC0b01ac058004d5c1."},{"issue":"6","key":"10.1016\/j.biologicals.2014.07.003_bib56","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1399-3089.2004.00181.x","article-title":"Assessing the risk potential of porcine circoviruses for xenotransplanation: consensus primer-PCR-based search for a human circovirus","volume":"11","author":"Hattermann","year":"2004","journal-title":"Xenotransplantation"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105614000748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105614000748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:39:34Z","timestamp":1589243974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105614000748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1045105614000748"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2014.07.003","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adventitious agents in viral vaccines: Lessons learned from 4 case studies","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2014.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}